- World Pharma News Home » Clinical Trials » FDA grants fast track designation for Boehringer Ingelheim's BIBW 2992
(a free service delivered by FeedBurner)
Boehringer Ingelheim's investigational cancer treatment BIBW 2992 has recently received a Fast Track Designation status by the FDA. Under this designation, Boehringer Ingelheim will conduct a pivotal trial programme studying BIBW 2992 in a non-small cell lung cancer (NSCLC) patient group where prior treatment with reversible EGFR inhibitors has failed.
The FDA's Fast Track Programme will facilitate the development programme and expedite the review of new treatments that demonstrate the potential to address an unmet medical need in serious or life-threatening diseases.
Discuss Add this link to... Bury
The FDA's Fast Track Programme will facilitate the development programme and expedite the review of new treatments that demonstrate the potential to address an unmet medical need in serious or life-threatening diseases.
Discuss Add this link to... Bury
Comments